Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Biosimilars Cardiorenalmetabolic Dermatology Gastroenterology Hematology Hepatology Immunology Infectious Disease Mental Health Neurology Obesity Oncology Ophthalmology Pulmonology Rare Disease Respiratory Rheumatology Women's Health

Free In-Person Regional Events Focused on Oncology and Population Health

Biosimilars Center on Health Equity & Access Digital Health Formulary Gene Therapy Guidelines Health Care Administration Health Care Cost Health Care Delivery Insurance Policy Population Health Product Approvals and Launches Technology Value-Based Care

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

Pooja Gokhale, PharmD

home / authors / pooja-gokhale-pharmd

Articles

AJMC original research clinical

Cost-Effectiveness Analysis of Ubrogepant, Rimegepant, and Zavegepant for Acute Migraine Treatment vs Usual Care

November 18th 2025

Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine.

Editorial Boards

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences
AJMC®
All rights reserved.